Natco Pharma to acquire Dash Pharma
Hyderabad: Drug maker, Natco pharma, has recently announced that the company through its affiliates is proposing to enter into an agreement to acquire 100 percent stake in Dash Pharmaceuticals LLC.
The acquisition is subjected to satisfactory completion of due diligence, execution of definitive agreements and compliance with statutory requirements. This acquisition provides NATCO with a front-end to engage with its customers directly in the USA which is the largest pharmaceutical market in the world.
"The indicative time period for completion of the acquisition is January 31, 2022," the company informed in a BSE filing.
The company further informed that the nature of consideration for the deal is US$ 18 million in cash.
Dash is a front-end pharmaceutical sales, marketing and distribution entity based in New Jersey, USA which is expected to have approximate net sales of USD 15 million for the year ending December 2021.
Read also: Natco Pharma launches cancer drug Tipanat in India
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc
Read also: Natco Pharma Marketing Partner Launches Generic Version Of Afinitor In US
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd